A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study

Gynecologic Oncology
Thomas F RoceretoRobert S Mannel

Abstract

To evaluate the effectiveness and toxicity of mifepristone in patients with ovarian, peritoneal and fallopian tube cancers. Patients with confirmed epithelial ovarian, peritoneal and fallopian tube cancers which were persistent or recurred in less then 1 year after primary chemotherapy were entered into this study. Patients were given mifepristone 200 mg by mouth daily for a 28 day cycle. The medication was stopped for unacceptable toxicity or tumor progression. Twenty-four patients were entered into the study. Twenty-two patients were evaluable for response. Only one patient had a partial response for a response rate of only 4.5% (90% confidence interval: 0.2%, 19.8%). Mifepristone has not proven to be an effective agent in the treatment of patients with recurrent or persistent ovarian, peritoneal and fallopian tube cancers.

References

Feb 1, 1991·Endocrine Reviews·B R Rao, B J Slotman
Jun 1, 2000·Gynecologic Oncology·T F RoceretoJ Paulson

❮ Previous
Next ❯

Citations

Apr 14, 2012·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Nagahiro Saijo
Sep 26, 2014·Reproduction : the Official Journal of the Society for the Study of Fertility·Alicia A Goyeneche, Carlos M Telleria
Jul 8, 2011·Cancer Management and Research·Gina M Mantia-SmaldoneAnda M Vlad
Oct 10, 2012·Endocrine-related Cancer·Francesmary ModugnoSteffi Oesterreich
Oct 27, 2015·Translational Oncology·Jenny-Maria JönssonIngrid Hedenfalk
Jan 15, 2015·Journal of Molecular Endocrinology·Caroline H DiepCarol A Lange
Apr 8, 2016·Clinical Medicine Insights. Oncology·Ioannis A Voutsadakis
Nov 3, 2010·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Terence C ChuaDavid L Morris
Oct 16, 2018·The Cochrane Database of Systematic Reviews·Jo MorrisonAndrew Bryant
Aug 5, 2011·Drugs·R Wendel Naumann, Robert L Coleman
Feb 22, 2012·Clinical Obstetrics and Gynecology·Tate Thigpen
Jun 12, 2014·Drugs·Raewyn M Poole, Asha Vaidya
Nov 28, 2017·Current Opinion in Obstetrics & Gynecology·Laura Paleari, Andrea DeCensi
Feb 22, 2012·Clinical Obstetrics and Gynecology·Leigh G SeamonLarry J Copeland
May 5, 2020·Endocrine Reviews·Md Soriful IslamJames Segars
Feb 11, 2020·Frontiers in Bioengineering and Biotechnology·Yasunari Matsuzaka, Yoshihiro Uesawa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Russell J SchilderBarbara C Vanderhyden
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Robert A BurgerJoel Sorosky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Stephen A CannistraWilliam McGuire
© 2022 Meta ULC. All rights reserved